888216-25-9 | Ganetespib (ZINC43130413)

Chemical type

• Synthetic Hsp90 inhibitor
• Resorcinol derivative

^[1]

• Non-benzoquinone ansamycin Hsp90 inhibitor

^[2]

Key properties

• Binding energy of -8.7 kcal/mol
• Molecular weight 364.41 g/mol, cLogP 3.254
• Inhibits Hsp90 function in tumor cells
• Tested in clinical trials with significant anti-cancer activity

^[1]

• Targets ATP-binding domain of Hsp90
• Attenuates pro-inflammatory signaling and immune responses
• Reduces epidermal thickness, dermal leukocyte infiltration, and scratching behavior in AD models
• Well-tolerated topically with no systemic toxicity; causes mild weight loss (approx. 6%) when administered systemically

^[2]

• Hsp90 inhibitor
• Anti-cancer agent in human trials

^[1]

• Therapeutic agent for ameliorating inflammation in atopic dermatitis
• Potential treatment for other autoimmune/inflammatory skin diseases like psoriasis or bullous pemphigoid
• Administered intraperitoneally (25 mg/kg) or topically (0.5 µmol)

^[2]

Classification by use

• Anti-cancer agents targeting molecular chaperones
• Chemicals in clinical development for oncology

^[1]

• Anti-inflammatory agents
• Immunomodulators
• Hsp90 blockers

^[2]

A trustworthy factory and manufacturer

1. [Cite:1] Exploring the inhibitory mechanism of resorcinylic isoxazole amine NVP-AUY922 towards the discovery of potential heat shock protein 90 (Hsp90) inhibitors, Scientific African, Volume 15, March 2022, e01107
2. [Cite:2] Heat shock protein 90 (Hsp90) inhibitor STA-9090 (Ganetespib) ameliorates inflammation in a mouse model of atopic dermatitis, Cell Stress and Chaperones, Volume 28, Issue 6, November 2023, Pages 935-942